

October 17 - 19, 2007

Bethesda North Marriott Hotel &  
Conference Ctr.  
N.Bethesda, Maryland

# 2007 CARDIOVASCULAR BIOMARKERS AND SURROGATE ENDPOINTS SYMPOSIUM

*ASSESSING CARDIOVASCULAR RISK AND PROGRESSION  
October 17-19, 2007 Bethesda, MD*

## *PRELIMINARY* PROGRAM AND REGISTRATION

**Co-Chair—Peter Libby, M.D.**  
*Mallinckrodt Professor of Medicine  
Harvard Medical School and  
Chief Cardiovascular Medicine  
Brigham and Women's Hospital*

**Co-Chair—Jean-Claude Tardif, M.D**  
*Director, Research Center  
Professor of Medicine  
CIHR Chair in Atherosclerosis  
Montreal Heart Institute*

***The objectives of this program are to:***

- ***Provide the latest information on cardiovascular imaging technology, in-vitro biomarkers, and the use of genomics, proteomics, and metabolomics***
- ***Identify challenges in the development, validation, and application of cardiovascular biomarkers and seek strategies to improve successful outcome***
- ***Create efficiencies toward improved patient healthcare***

*This meeting is co-sponsored by:*



[U. S. Department of Health and Human Services](#)  
[U. S. Food and Drug Administration](#)  
[Center for Food Safety and Applied Nutrition](#)



**Montreal Heart Institute**  
*Coordinating Center*



# 2007 CARDIOVASCULAR BIOMARKERS AND SURROGATE ENDPOINTS SYMPOSIUM WELCOME

Dear Colleague:

We are pleased to invite you to participate in the 5th Annual Cardiovascular Biomarkers and Surrogate Endpoints Symposium. This outstanding scientific program addresses current approaches for assessing and managing cardiovascular risk, as well as strategies for advancing the use of biomarkers and innovative technologies for cardiovascular disorders. Given the growing prevalence of cardiovascular disease and an expanding population at risk for future events, healthcare systems will likely face more pressure, rather than less, in coming years. We urgently require tools to address the residual burden of cardiovascular risk that represents a major challenge to human health worldwide. Future biomarker efforts are an integral part of this toolbox and we must continue to build on knowledge gained from basic research efforts and clinical evaluations, incorporating lessons from past successes and failures. The Cardiovascular Biomarkers and Surrogate Endpoints Symposium is designed to share knowledge and encourage the collaborative efforts needed to accelerate the development of improved cardiovascular diagnostics and therapeutic strategies.

Join us to learn how to translate the latest research findings to improve patient healthcare. Presentations from government, academic, industry, and healthcare thought-leaders will examine the issues surrounding the effective assessment and application of cardiovascular biomarkers and imaging technologies. We wish to express sincere thanks to all of you who have helped get this annual symposium off to a successful start. To keep up the momentum, we encourage everyone to attend this year's annual meeting and to spread the word within your organizations and local institutions. Only with your support can we advance the field of cardiovascular biomarkers and find efficiencies toward improved healthcare.

Sincerely,



Peter Libby  
Chief, Cardiology  
Brigham and Women's Hospital



Jean-Claude Tardif  
Director of Research  
Montreal Heart Institute



Therese Heinonen  
Associate Director  
Montreal Heart Institute

## SCIENTIFIC SESSION PRESENTATIONS

Established and Emerging In-vitro Biomarkers	Arterial Tonometry
Established and Emerging Imaging Technologies	Genomics of Inflammation
Proteomics, Metabolomics, Genomics and Nanotechnology	Biomarker Economics
FDA Critical Path Initiative and Priority List	Lipoproteins and Other Related Risk Factors
Evidentiary Standards and Validation Challenges	Advanced Clinical Trial Design
Maximizing Biomarker Utility—Obstacles and Strategies	Drug Development Strategies
Biomarkers in Risk and Therapeutic Assessment	Biomarkers as Safety Surrogates
Biomarker initiatives and Collaborative Models	Heart Failure Biomarkers
Biomarker Logistics and Administration	Atherothrombotic Disease and Marker Identification
Development of Novel In-Vitro Diagnostics	Evidence Based Technology Assessments
Biomarkers of Arrhythmia and Sudden Death	Use of Biomarkers for Regulatory Decision-Making
Cardiovascular Markers in Food Safety and Nutrition	Cardiac Safety Research Consortium
Biomarkers in CV Medical Device Development	The Biomarkers Consortium Update
Biomarkers in Model-Based Drug Development	
Perspectives and Initiatives from the US Center for Disease Control	
Advances in Cardiovascular Nuclear Medicine and Potential Economic Impact	
Regulatory Considerations for Soluble and Imaging Biomarker Applications	
Integrating Biomarkers into Practice: The Need for Data on Clinical Outcomes	

## AGENDA OVERVIEW

Wednesday, October 17th

8:00 am Overview of Technologies  
noon Complimentary lunch/Breakouts  
1:30 pm Technologies and Panel Discussion  
5:45 pm Session ends  
7:00 pm Reception

Thursday, October 18th

8:00 am Efficiencies and Trial Design  
noon Complimentary lunch/Breakouts  
1:30 pm Initiatives, Collaborations and Panel  
5:45 pm Session ends

Friday, October 19th

8:00 am Perspectives, Policy and Panel  
1:00 pm Closing Remarks

### CME

The Continuing Medical Education (CME) office of the University of Montreal, Canada designates this an education activity. The CME office of the University of Montreal, Canada is fully accredited by the Canadian Association of Medical Schools (CACMS), by the Quebec College of Physicians (QCP), and by reciprocity by the American Council of CME (ACCME). If you would like to receive a statement of credit, you must attend the program and return the credit request and evaluation form provided at the registration desk.

# FACULTY

Peter Libby, M.D. – Program co-chair  
Mallinckrodt Professor of Medicine  
Harvard Medical School and  
Boston, MA

Jean-Claude Tardif, M.D. – Program co-chair  
Director, Research Center  
Montreal Heart Institute  
Montreal, Quebec

Eric Abadie, M.D.  
Director, Therapeutics Evaluation, AFSSAPS  
European Medicines Agency (EMA)  
Paris, France

Christine Albert, M.D., MPH  
Director, Center for Arrhythmia Prevention  
Harvard Medical School  
Boston, MA

Naomi Aronson, Ph.D.  
Executive Director, Technology Evaluation Center  
Blue Cross and Blue Shield Association  
Chicago, IL

Robert S. Balaban, M.D., Ph.D.  
National Heart, Lung and Blood Institute  
National Institutes of Health  
Bethesda, MD

Colin Berry, BSc., Ph.D.  
Cardiovascular MRI / CV Intervention Program  
NHLBI, National Institutes of Health  
Bethesda, MD

Stefan Blankenberg, M.D.  
Department of Medicine  
University of Mainz  
Mainz, Germany

Eric P. Brass, M.D., Ph.D.  
Professor of Medicine  
Harbor-UCLA Medical Center  
Torrance, CA

W. Virgil Brown, M.D.  
Charles Howard Candler Professor of Medicine  
Emory University School of Medicine  
Atlanta, GA

Robert M. Califf, M.D.  
Vice Chancellor for Clinical Research  
Director, Duke Translational Medicine Institute  
Durham, NC

Jean Davignon, M.D.  
Director Hyperlipidemia and Athero Research  
Clinical Research Institute of Montreal  
Montreal, Quebec

James De Lemos, M.D.  
Associate Professor and CCU Director  
University of Texas-Southwestern Medical School  
Dallas, TX

Zahi A. Fayad, Ph.D.  
Professor, Departments of Radiology and Medicine Mount  
Sinai School of Medicine  
New York, NY

Felix W. Frueh, Ph.D.  
Office of Clinical Pharmacology  
CDER, U.S. Food and Drug Administration  
Silver Springs, MD

Federico Goodsaid, Ph.D.  
Office of Clinical Pharmacology  
CDER, U.S. Food and Drug Administration  
Silver Spring, MD

Therese Heinonen, D.V.M.  
Associate Director, Medical and Scientific Affairs  
Montreal Heart Institute  
Montreal, Quebec Canada

Agnes Klein, M.D.  
Director, Center for Evaluation of Radiopharmaceuti-  
cals and Biotherapeutics  
Biologics and Genetic Therapies Directorate  
Health Products and Food Branch, Health Canada  
Ottawa, Ontario

G. B. John Mancini, M.D.  
Professor of Medicine, Division of Cardiology  
Director, CV Imaging Core Lab Vancouver Hospital  
Head, Department of Medicine, University of B.C.  
Vancouver, British Columbia

Elizabeth Mansfield, Ph.D.  
Senior Policy Analyst  
Office of In Vitro Diagnostic Device Evaluation and  
Safety, Center for Devices and Radiological Health  
US Food and Drug Administration  
Rockville, MD

David O. Meltzer, M.D., Ph.D.  
Director of the Center for Health and Social Sciences  
Department of Medicine and Dept. of Economics  
University of Chicago  
Chicago, IL

George A. Mensah, M.D.  
Chief Medical Officer,  
National Center for Chronic Disease Prevention and  
Health Promotion  
Centers for Disease Control and Prevention  
Atlanta, GA

Christopher O'Donnell, M.D.  
Senior Advisor to the Director for Genome Research  
Associate Director of the Framingham Heart Study  
NHLBI, National Institutes of Health  
Bethesda, MD

Mary Parks, M.D.  
Division of Metabolism and Endocrine Products  
Center for Drug Evaluation and Research  
US Food and Drug Administration  
Silver Spring, MD

Robert Powell, PharmD  
Director, Pharmacometrics  
Office of Clinical Pharmacology  
Center for Drug Evaluation and Research  
US Food and Drug Administration  
Silver Springs, MD

Gurvaneeet Randhawa, M.D.  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality  
Silver Spring, MD

Paul M. Ridker, M.D.  
Eugene Braunwald Professor of Medicine  
Center for Cardiovascular Disease Prevention  
Brigham and Women's Hospital  
Boston, MA

John Rioux, Ph.D.  
The Laboratory of Genetics and Genomic Medicine of  
Inflammation  
Université de Montréal and Montreal Heart Institute  
Montreal, Quebec

Daniel Schultz, M.D.  
Director, Center for Devices and Radiological Health  
US Food and Drug Administration  
Rockville, MD

Norman Stockbridge, M.D.  
Division of Cardio-Renal Drug Products  
Center for Drug Evaluation and Research  
US Food and Drug Administration  
Silver Spring, MD

Allen Taylor, M.D.  
Chief, Cardiology Service  
Walter Reed Army Medical Center  
Washington, DC

Douglas C. Throckmorton, M.D.  
Deputy Center Director  
Center for Drug Evaluation and Research  
US Food and Drug Administration  
Rockville, MD

Paula R. Trumbo, Ph.D.  
Team Leader, Nutrition Science Evaluation  
Center for Food Safety and Applied Nutrition  
US Food and Drug Administration  
College Park, MD

David Waters, M.D.  
Chief, Cardiovascular Medicine  
University of California  
San Francisco, CA

Ralph Weissleder, M.D., Ph.D.  
Director, Center for Molecular Imaging Research  
Professor of Radiology, Harvard Medical School  
Boston, MA

## INDUSTRY FACULTY INCLUDE

Jonathan Allis, Ph.D.  
Global Head, Imaging Technology  
General Electric Healthcare

Donald M. Black, MBA, M.D.  
Global Head of Research and Development  
General Electric Healthcare

Jay M. Edelberg, M.D., Ph.D.  
Director, Cardiovascular Biomarkers  
Clinical Pharmacology & Discovery Medicine  
GlaxoSmithKline

Giora Feuerstein, M.D.  
Assistant Vice President  
Head, Discovery Translational Medicine  
Wyeth Research

Michael Klimas, Ph.D.  
Executive Director, Imaging Franchise Lead  
Merck & Co., Inc.

Gary F. Mitchell, M.D.  
Cardiovascular Engineering, Inc.  
Waltham, MA

David G. Orloff, M.D.  
Medical Director  
Medpace, Inc.

Joel Raichlen, M.D.  
Senior Director, Clinical Research  
AstraZeneca

Amy E. Rudolph, Ph.D.  
Clinical Director  
Global Medical CV Metabolic Endocrine  
Pfizer, Inc

William J. Sasiela, Ph.D.  
Chief Medical Officer  
Aegerion Pharmaceuticals, Inc.

John Wagner, MD, Ph.D.  
Director, Clinical Pharmacology  
Merck & Co., Inc.

James J Zhang, M.D., Ph.D., MBA  
Global Clinical Development  
Siemens Molecular Imaging, Inc  
Siemens Medical Solutions USA

October 17 - 19, 2007

Bethesda North Marriott  
Hotel & Conference Ctr.  
N. Bethesda, Maryland

**2007 CARDIOVASCULAR BIOMARKERS AND  
SURROGATE ENDPOINTS SYMPOSIUM  
OCTOBER 17 - 19, 2007**

*Please Print Clearly*

Prefix	First Name	Last Name	Degree Initials
Title		Organization	
Mailing Address		City	State/Province/Region
Billing Address*		City	State/Province/Region
Postal Code	Country	Email Address	
Phone Number		Fax Number	

**\*If paying by credit card, billing address must match address of credit card holder.**

Visa     
  MasterCard     
  American Express     
 **(please circle card being charged)**

Account Number	Valid Thru	Signature
----------------	------------	-----------

**Registration Fee:**

<b>Registered on or before August 17, 2007</b>	_____	<b>\$795.00</b>
<b>Registered after August 17, 2007</b>	_____	<b>\$895.00</b>
<b>Government employee (full-time)</b>	_____	<b>\$595.00</b>

Payment must be received prior to October 15<sup>th</sup>. Registrations will be confirmed by email or fax.

**Cancellation and Refund Policy Deadlines**

All cancellation requests must be made in writing and sent to Clinical Lynx, Inc. Registrants who submit cancellation requests that are received on or before September 15, 2007 will receive a refund equal to the registration fee paid less a \$100 administrative fee. Registrants who submit cancellation requests that are received between September 16 and October 15, 2007 will receive a refund equal to fifty percent (50%) of the registration fee paid. Cancellation requests received on or after October 15, 2007 will not be honored and no portion of the registration fee will be refunded.

Please note in the event that the 2007 Cardiovascular Biomarkers and Surrogate Endpoints Symposium is abbreviated or cancelled because of fire, explosion, strike, freight embargo, epidemic, catastrophe, act of God, or the act of a public enemy including, but not limited to, an act of any government, de jure or de facto or agency or official thereof, Clinical Lynx, Inc. reserves the right, in its sole discretion to unilaterally terminate the conference. In such cases, the registrant hereby agrees to waive any claim he, she or it may have against Clinical Lynx, Inc. for damages or compensation, including but not limited to fees for registration, housing, airfare and incidental charges.

Hotel Accommodations

Participants are responsible for making their own hotel and travel arrangements. To secure your room at the Bethesda North Marriott, please contact the Bethesda North Marriott Reservations at 800-859-8003 and state you are attending the Biomarkers Symposium (Group code: CVBCVBA) to receive a discounted room rate. **Space is Limited, so reserve early.**

**REGISTER ONLINE: [www.cmod.org](http://www.cmod.org)**

*Fax registration accepted for credit card payment only. Otherwise, mail the registration form and fee payable to Clinical Lynx, Inc. at 828 West Grand River Ave., Brighton, MI, 48116 USA*

Phone: 810-494-7133      Fax: -810-494-7122      E-mail: [symposium@clinicallylnx.com](mailto:symposium@clinicallylnx.com)